BioSpace News Archive

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended March 31, 2023.

Envision Pharma Group (Envision) has appointed Dr. Jennifer Costello, PharmD, BCPS, CMPP, to the role of Chief Medical Officer.

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2023.

Henry Schein, Inc. announced an agreement to acquire S.I.N. Implant System, one of Brazil’s leading manufacturers of dental implants, pending regulatory approval.

Bausch Health Companies Inc. today announced its first-quarter 2023 financial results.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the first quarter 2023, recent business highlights, and upcoming milestones.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that the Board of Directors declared a special cash dividend of $0.45 per share on the common stock of the Company.

Theratechnologies Inc. today presented data from a landmark study in which the use of ibalizumab, a monoclonal antibody antiretroviral therapy (ART) commercialized as Trogarzo®, was associated with favorable virologic outcomes compared to non-ibalizumab regimens used in routine care in heavily treatment-experienced people with HIV.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2023 financial results on Thursday, May 11, 2023 and will provide a business update.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the first quarter ended March 31, 2023 and provided an update on the Company’s operations.